Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. - Wikidata - awgldk - TriplyDB

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q33394947

about

Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association data Chronic lymphocytic leukemia: a clinical review including Korean cohorts New developments in the management of chronic lymphocytic leukemia: role of ofatumumab Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia Ibrutinib (PCI-32765) in chronic lymphocytic leukemia New antibody approaches to lymphoma therapy Novel CD20 monoclonal antibodies for lymphoma therapy Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.Ofatumumab combined with chlorambucil for previously untreated chronic lymphocytic leukemia: a phase I/II, open-label study in Japan.Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes Management of chronic lymphocytic leukemia.Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients Advances in treating chronic lymphocytic leukemia Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?Choosing first-line therapy for chronic lymphocytic leukemia.Therapeutic antibodies against cancer.Initial treatment of CLL: integrating biology and functional status.Therapeutic advancement of chronic lymphocytic leukemia.Chronic lymphocytic leukemia: inception to cure: are we there?Ibrutinib: a paradigm shift in management of CLL.Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies.ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).What do we do with chronic lymphocytic leukemia with 17p deletion?Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.The role of monoclonal antibodies in the treatment of lymphomas.The current status and future impact of targeted therapies in non-Hodgkin lymphoma.Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia.The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy.Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.New treatment options for chronic lymphocytic leukemia.Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.

P2860

Q24203027-CAA64A6A-6D05-4DC6-843B-315A206D2ED3 Q26738934-C09FD881-3B9D-484E-9E67-F2F3D0B1C1D3 Q26752467-3960A272-525E-4C91-8018-95EFC53BE93D Q26768396-139DA6B2-C9AC-45B6-BC7B-DD291CB12A92 Q26783600-3E15C028-1CF9-479A-AB47-DED9CEB5111F Q26852328-C9150285-6BEA-426C-823B-0EB26A430B25 Q27022373-EA785F48-8E34-444D-8696-2BF02C710849 Q28390112-703A0CCB-E1EA-46F1-83F9-2DE7FE3BCA31 Q30405847-FAE9A100-39D4-4C1A-9A6E-666FE100FD26 Q33406478-537EFB3E-330F-4A3A-850B-036C8EBBE1B8 Q33419843-0F861872-49A7-48FC-88FC-0292A04E2192 Q33441123-C16C89B2-4ABD-4EA3-9AE0-E8DFAFFD774D Q33558148-95078E94-9C70-484F-847E-64D6FF04E593 Q33695912-95ADBDB5-798C-41A4-9516-EB41A45F4FD1 Q33903379-CCC242FD-6729-4B6D-A52F-73D41EB8D39D Q34019917-603C79F0-042B-4F9B-B08C-DCCEFDCB90BE Q34625543-EE86E944-A1ED-43E0-8C69-101C458575F8 Q35124844-77357D5F-2DCC-4960-B514-B17CE2319032 Q35908498-54DF01DA-114A-4DBE-9CC2-8447F0171581 Q36219647-022D7B92-9303-4D59-800D-77D6CC43E97C Q36300303-EDD14EB4-58C8-4224-8394-A8978863025B Q36609259-B94DE1F5-2B92-4B65-B751-52F659062E48 Q36739295-DA4EFC49-40D2-4CDB-B71E-722128FDE875 Q37178611-F2B563DC-CDC2-4737-8879-4DABEE0C1403 Q37487919-2D865CA5-007F-41EB-BA88-28CB391E2B48 Q37975154-E0123DC4-C21A-469F-BB6B-AC1EC6F7A9A7 Q37980900-636AF87A-0353-4495-AA21-6F6E0BF35187 Q38029382-8F4224CF-3E5A-4E73-9665-E607548E432E Q38061883-58EC63E9-282C-4AC9-89E6-B12FBBDEF345 Q38063170-DC98305A-F71A-44CA-84E3-5CF25305FFBE Q38068494-85A96370-B3F8-41D4-BAD6-B7ED5AC07F6B Q38068932-8CE080D7-2A9A-49E2-A170-707368F77B4D Q38069595-3F469445-2499-4683-8758-DE78D3002019 Q38095123-55748777-7D13-42CC-93A9-9D22FF186114 Q38100787-6AACAAD0-1472-4B37-8D14-633ECA755910 Q38126946-507EC9F8-9900-4843-B271-D4B1C135CD14 Q38155343-0DAF1F96-111B-4EBB-A792-77F03115989E Q38190095-ECFB7D65-3EE1-4153-A0A5-2F1F57FC2C1E Q38221686-198BD12A-D0B6-4ADC-86AE-2FA3FD06BA3C Q38231432-8841ABCA-084D-47E8-A7EC-4D66435AC561

P2860

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q33394947

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Chemoimmunotherapy with O-FC i ...... chronic lymphocytic leukemia.

@ast

Chemoimmunotherapy with O-FC i ...... chronic lymphocytic leukemia.

@en

type

label

Chemoimmunotherapy with O-FC i ...... chronic lymphocytic leukemia.

@ast

Chemoimmunotherapy with O-FC i ...... chronic lymphocytic leukemia.

@en

prefLabel

Chemoimmunotherapy with O-FC i ...... chronic lymphocytic leukemia.

@ast

Chemoimmunotherapy with O-FC i ...... chronic lymphocytic leukemia.

@en

P1433

Q33394947-4167CF59-0869-453A-BDCE-AF1488511615

P1476

Q33394947-5F3AF9C3-0FAA-45DC-8B48-73107E62EB5A

P2093

Q33394947-11EA40BB-3635-4848-B6B6-71C9C1457751

Q33394947-13A50546-651A-41B4-ADB6-2C732AA852C4

Q33394947-1669C0AE-6264-4960-9729-6E1D782DA203

Q33394947-1A83CC25-B3DF-4E4F-9947-73594293D10B

Q33394947-266C0F60-7207-4182-ABE0-47BBC72550E4

Q33394947-48F1512F-BAC5-442F-A1DA-260A45D9E579

Q33394947-6853CA16-F944-4E11-8056-3A6B8DA00D7C

Q33394947-7277527A-C456-4334-BE9F-7AD7ED29B16B

Q33394947-78EF366D-1923-452D-9321-0DB045D94F3F

Q33394947-796E06E5-A408-4ACB-A44F-6776ED4C02CB

P2860

Q33394947-0254E5D3-8423-49E1-8C48-FA1752195E3C

Q33394947-0F4FE251-8BB9-4666-B60E-7BDD6F3FC226

Q33394947-15DD56A3-4753-414A-B18B-C6D09C701B5C

Q33394947-216ED8D0-F75A-4646-8FAC-A57D63E6BAE0

Q33394947-62B1D983-AFD5-4C1A-8CC0-70E6AD537723

Q33394947-6DCAE028-A0FD-49ED-A708-3970D0C4892F

Q33394947-70A0C26A-06B4-48E6-8534-FF7785E1325F

Q33394947-75347ACE-C802-440C-A663-594DC50DCD38

Q33394947-76F83CA2-A86D-4BFB-B1C7-7285672B4D39

Q33394947-7E7BDC39-285B-474D-AC36-08CA0F920A31

P304

Q33394947-D8542733-6E12-4D5F-8718-F653233CFC81

P31

Q33394947-E199DA21-4DA6-4F77-86E0-29B3B5B3D973

P356

Q33394947-A081D567-24FB-459D-A706-0981DC6BE094

P407

Q33394947-B3ABFF72-E216-42F5-9AB2-2BFAA8BDC94F

P433

Q33394947-C8258F81-43C5-423C-B72E-938E90DE290F

P478

Q33394947-78494557-9E8C-43EB-B529-52C9A0C00525

P50

Q33394947-15FE631C-3FE8-4E3B-824B-04B98389008B

Q33394947-3769C598-BADC-45FC-ADA2-592BC2FEE6D2

Q33394947-B10245E3-AC04-4FA3-8A6F-D166AA9294A3

P577

Q33394947-529C2CA9-3EAF-4F5E-B42C-303CA79A95AE

P5875

Q33394947-1E186A2D-7DAC-4D72-B679-2E024F51151C

P698

Q33394947-838786DE-4713-439E-AD32-76E77AB07512

P921

Q33394947-570E644E-D31D-4D00-8F25-589ACDDCCAF2

Q33394947-A09E6228-35F9-4572-A8DA-841219BDC535

P932

Q33394947-FAD798FA-DB2C-4C35-8169-776255AD3B45

P356

BLOOD-2010-12-323980

P1433

P1476

Chemoimmunotherapy with O-FC i ...... chronic lymphocytic leukemia.

@en

P2093

407 Study Investigators

http://www.w3.org/2001/XMLSchema#string

Chai-Ni Chang

http://www.w3.org/2001/XMLSchema#string

Charlotte A Russell

http://www.w3.org/2001/XMLSchema#string

Francisco J Hernandez-Ilizaliturri

http://www.w3.org/2001/XMLSchema#string

Geoffrey Chan

http://www.w3.org/2001/XMLSchema#string

Georg Hess

http://www.w3.org/2001/XMLSchema#string

Ira Gupta

http://www.w3.org/2001/XMLSchema#string

Jan Dürig

http://www.w3.org/2001/XMLSchema#string

Jirí Mayer

http://www.w3.org/2001/XMLSchema#string

Laimonas Griskevicius

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Cancer statistics, 2010

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

Genomic aberrations and survival in chronic lymphocytic leukemia

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

P304

6450-6458

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-12-323980

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Stephan Stilgenbauer

Swaminathan Padmanabhan

William G Wierda

P577

2011-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51056541

http://www.w3.org/2001/XMLSchema#string

P698

21498674

http://www.w3.org/2001/XMLSchema#string

P921

P932

4916561

http://www.w3.org/2001/XMLSchema#string